Clinical Trial

Characterizing Outcomes and Real-World Experience of Cardiac Physiologic Pacing (The CORE-CPP Study)

Study acronym: CORE-CPP
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to use real-world evidence to validate that conduction system pacing (CSP), delivered via a Medtronic 3830 catheter-delivered lead and a Medtronic dual-chamber transvenous pacemaker, is a safe and effective alternative to biventricular pacing (BVP) in patients indicated for cardiac resynchronization therapy (CRT) to deliver cardiac physiologic pacing (CPP), as documented in the clinical literature.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-18; most recent amendment 2026-04-27.
Trial Details
NCT Number NCT06606288
Lead Sponsor Medtronic Cardiac Rhythm and Heart Failure
Conditions Heart Failure
Enrollment 6,000 participants
Start Date 2017-01-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29